Live tape
Top 8, mentions 7d9,330GOOGL1,862 mentions▲ +0.04SNDK1,524 mentions▲ +0.11NVDA1,134 mentions▲ +0.08META1,121 mentions▲ +0.03SPCX1,080 mentions▲ +0.08NBIS970 mentions▲ +0.09HTZ838 mentions▲ +0.09VOO801 mentions▲ +0.09

Equity · Healthcare

DNA

Ginkgo Bioworks Holdings, Inc. · NYSE

$8 0.00% 1D Finazon · prior-day close · Jul 31, 2026
Price · Chart
Our own end-of-day closes 49 sessions
$11 $7 21 May 31 Jul

The line runs $8 on 21 May through $8 on 31 July, on a scale from $7 to $11. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of DNA over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 49 sessions over that window: $8 on 21 May 2026 through $8 on 31 July 2026.

Market cap $443.7M
52-week range $5 – $16.15
Avg volume 209.7K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 19, 2026

DNA insider trades

SEC Form 4 · last 90 days · newest reported trade 17 Jul 2026
Open-market buys 0
Open-market sells 2
Net sold $9K
Non-trade filings 2
Date Insider Type Shares Value
17 Jul 2026 Coen Steven P. See remarks Sell 752 $6K
22 May 2026 Coen Steven P. See remarks Sell 307 $3K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
16 Jul 2026 Coen Steven P. See remarks Option exercise 1,486
21 May 2026 Coen Steven P. See remarks Option exercise 743

DNA reported financials

SEC EDGAR XBRL

DNA reported revenue of $170.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$312.8M.

Figure Reported Period
Revenue $170.2M 31 Dec 2025 fiscal year
Net income −$312.8M 31 Dec 2025 fiscal year
Diluted EPS −$5.64 31 Dec 2025 fiscal year
Total assets $990.0M 30 Jun 2026 at period end
Total equity $420.3M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

DNA earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 — $20M
31 Mar 2026 Q1 2026 — $19M
31 Dec 2025 FY 2025 $-5.64 $170M
30 Sep 2025 Q3 2025 $-1.45 $39M
30 Jun 2025 Q2 2025 $-1.10 $39M
31 Mar 2025 Q1 2025 $-1.68 $38M
31 Dec 2024 FY 2024 $-10.54 $227M
30 Sep 2024 Q3 2024 $-1.08 $89M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

DNA institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a DNA position for the quarter ended 30 Jun 2026 — a combined $61.0M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) 3,577,128 $35.4M
Millennium Management Added +30.9% shares 638,676 $6.3M
AQR Capital Management Added +110.9% shares 621,625 $6.2M
Renaissance Technologies Added +437.4% shares 539,856 $5.3M
Tudor Investment Corp Trimmed −27.8% shares 335,710 $3.3M
D. E. Shaw & Co. Added +457.1% shares 151,356 $1.5M
Citadel Advisors New position 130,935 $1.3M
Marshall Wace New position 77,937 $772K
Two Sigma Investments Held (±25%) −5.0% shares 60,454 $599K
Man Group Trimmed −77.8% shares 24,208 $240K

Source: SEC EDGAR 13F filings

DNA fails-to-deliver

SEC CNS data

On 23 Jul 2026, 1 shares of DNA failed to deliver (about $8) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
23 Jul 2026 1 $8 <0.001%
22 Jul 2026 1,001 $8K 0.002%
17 Jul 2026 3,534 $29K 0.006%
15 Jul 2026 7 $63 <0.001%
09 Jul 2026 9,443 $86K 0.017%

Source: SEC fails-to-deliver (CNS) data